These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Pyon EY Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461 [TBL] [Abstract][Full Text] [Related]
10. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. Riis BJ; Ise J; von Stein T; Bagger Y; Christiansen C J Bone Miner Res; 2001 Oct; 16(10):1871-8. PubMed ID: 11585352 [TBL] [Abstract][Full Text] [Related]
11. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Tankó LB; McClung MR; Schimmer RC; Mahoney P; Christiansen C Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686 [TBL] [Abstract][Full Text] [Related]